

About VETMEDIN® (pimobendan) Chewable Tablets

VETMEDIN® Chewable Tablets are beef-flavored and half-scored to meet the dosing needs of dogs who prefer chews.

In a study on dogs with congestive heart failure, more than half of dogs treated with VETMEDIN® products showed significant improvements in breathing and energy levels in as little as 7 days.¹

Dosage and Administration

VETMEDIN® Chewable Tablets should be given to your dog twice a day—morning and at night—approximately 12 hours apart. See your veterinarian as well as full prescribing information for more details.

Dosage and Administration FAQs

How do VETMEDIN® Brand Products work?

VETMEDIN® products have a dual mode of action, relaxing the blood vessels carrying blood to and from the heart, and improving heart muscle function to help the heart work more efficiently.

How long will my dog require treatment with VETMEDIN® Brand Products?

In the asymptomatic setting, you would begin providing your dog with VETMEDIN® Chewable Tablets or VETMEDIN® Solution. Your dog would remain on that medication to help control signs of heart failure until the end of the pet's life.

Do VETMEDIN® Brand Products have any side effects?

The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. Please speak to your vet if your dog experiences severe adverse reactions.

What should I do if I forget to give one of VETMEDIN® daily doses?

Wait until the next scheduled dosing time and resume the normal twice-daily (every 12 hours) pattern of dosing.

What should I do if my dog vomits shortly after dosing?

Speak to your vet. Some dogs in our clinical trials experienced transient mild vomiting that resolved after a few doses. If vomiting is severe or persistent, discontinue the medication and speak to your vet.

Whats the difference between VETMEDIN® brand vs a compounded pimobendan?

- VETMEDIN® is the only brand approved by the FDA that includes both tablet and liquid formulations to treat dogs with CHF due to MMVD and DCM.
- Compound-manufactured preparations using bulk substances are not equivalent to generic drug products. Generic drug products have demonstrated bioequivalence in safety and efficacy with the pioneer drug product approved by the FDA; compounded substances do not.²
- The FDA does not evaluate the safety of compounded formulations.
- Without an appropriate formulation process, compounded products may be formulated with unknown gastrointestinal absorption properties and uncertain efficacy.

1. Lombard CW, Jöns O, Bussadori CM; the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249–261.
2. Plumb DC (ed). Plumb's Veterinary Drug Handbook. 8th edition. Ames, Iowa: John Wiley & Sons, Inc.; 2015. 858–861.